Share General Information
Carbidopa, classified as a non-competitive decarboxylase inhibitor, is used in combination with the chemically related levodopa for the treatment of Parkinson’s disease or Parkinson-like symptoms (e.g. stiffness, shakiness, difficulty moving). Used alone, carbidopa has no effect on Parkinson’s symptoms. It is used to improve the effect of levodopa and reduce unwelcome side effects such as nausea. The drug works by preventing the breakdown of levodopa in the bloodstream, which allows more levodopa to enter the brain. Carbidopa has no anti-Parkinson effects by itself.
About the API
-
Japan DMF
-
Korea DMF
-
US DMF
The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.
For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.
